Nurix Therapeutics (NASDAQ:NRIX) Given Buy Rating at BTIG Research

BTIG Research reiterated their buy rating on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research note released on Thursday,Benzinga reports. BTIG Research currently has a $30.00 price target on the stock.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus set a $33.00 target price on shares of Nurix Therapeutics in a research note on Friday, October 10th. Oppenheimer lowered their price objective on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a research report on Friday, October 10th. Piper Sandler lifted their target price on Nurix Therapeutics from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday. Wells Fargo & Company boosted their price target on Nurix Therapeutics from $21.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Morgan Stanley set a $36.00 price objective on Nurix Therapeutics and gave the company an “overweight” rating in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $17.59 on Thursday. The company has a 50 day simple moving average of $18.50 and a two-hundred day simple moving average of $13.34. Nurix Therapeutics has a fifty-two week low of $8.18 and a fifty-two week high of $22.50. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -5.79 and a beta of 1.93.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Wednesday, January 28th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.02. The firm had revenue of $13.58 million during the quarter, compared to the consensus estimate of $13.41 million. Nurix Therapeutics had a negative return on equity of 60.99% and a negative net margin of 314.90%. On average, analysts forecast that Nurix Therapeutics will post -2.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,284 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at approximately $472,155.52. This trade represents a 14.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 7.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Wexford Capital LP purchased a new position in shares of Nurix Therapeutics during the 3rd quarter worth $41,000. Tower Research Capital LLC TRC raised its holdings in Nurix Therapeutics by 118.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after purchasing an additional 3,475 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Nurix Therapeutics by 66.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock worth $93,000 after purchasing an additional 1,970 shares during the period. Sherbrooke Park Advisers LLC purchased a new position in Nurix Therapeutics during the third quarter valued at $100,000. Finally, 49 Wealth Management LLC bought a new stake in Nurix Therapeutics during the third quarter valued at about $108,000.

Key Headlines Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Analyst upgrade: Royal Bank of Canada raised its price target to $30 and assigned an “outperform” rating, implying substantial upside vs current levels. Benzinga
• Positive Sentiment: Analyst confirmations: BTIG reaffirmed a “buy” rating with a $30 target, and Needham reaffirmed a “buy” with a $26 target — both signal continued analyst confidence in share appreciation. Benzinga
• Positive Sentiment: Clinical & corporate update: Nurix began dosing first patients in the DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL, presented supportive Phase 1 data at ASH 2025 (reported 83% ORR and 22.1‑month PFS), disclosed differentiated preclinical data for IRAK4 degrader GS‑6791 with Gilead, and ended the quarter with ~$592.9M in cash and marketable securities — items that materially improve execution and runway prospects. Corporate Update
• Neutral Sentiment: Quarterly results were mixed: NRIX reported a $0.82 loss per share, slightly better than consensus (-$0.86) and revenue of $13.58M vs. ~$13.41M expected — a modest beat on the headline numbers, but the company remains unprofitable with large negative margins. Press Release
• Negative Sentiment: Conflicting coverage: Zacks ran a headline framing the quarter as a loss that “misses revenue estimates,” which may create investor confusion despite the company-reported slight revenue beat — such mixed messaging can pressure the stock near earnings. Zacks

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.